Navigation Links
Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
Date:7/1/2008

he highest concentration in milk, is expressed throughout the body in immune cells and on all body surfaces exposed to the external environment. Lactoferrin plays an important role in helping to establish the immune system, including the Gut Associated Lymphoid Tissue (GALT), in infants. Talactoferrin is produced in Aspergillus niger, a filamentous fungus, and is structurally identical to native human lactoferrin in all material respects, differing only in its glycosylation.

Talactoferrin is an orally administered protein that mediates its activity through the gut and the GALT -- the largest lymphoid organ in the body. It acts through a novel mechanism of dendritic cell recruitment and activation. Following oral administration, talactoferrin is transported by the M-cells into the small intestinal Peyer's Patches, where it recruits circulating immature dendritic cells bearing tumor antigens to the GALT and induces their maturation. DC maturation in the presence of tumor antigens and lymphoid effector cells induces a strong systemic innate and adaptive immune response mediated by anti-cancer Natural Killer (NK) cells, CD8+ lymphocytes and NK-T cells. This results in the activation of tumor-draining lymph nodes, cellular infiltration of distant tumors and tumor-cell death. Mounting the initial immune response in the GALT -- away from the primary tumor and using a physiologically important pathway -- minimizes the effect of the cancer's local immunosuppressive defenses.

About Renal Cell Carcinoma (RCC) RCC is the most common type of kidney cancer, accounting for approximately 90 percent of kidney tumors. In the United States, RCC affects over 40,000 patients per year, and is responsible for close to 13,000 deaths. Kidney cancer is uncommon under age 45, and its incidence is highest between the ages of 55 and 84.

Once RCC is metastatic, it is difficult to treat, and median survival is between one and two years. A number of different modalities are av
'/>"/>

SOURCE Agennix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
4. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
5. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
8. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
9. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
10. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
11. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Exagen Diagnostics, Inc., a commercial-stage diagnostics ... for the accurate diagnosis and monitoring of patients ... its Avise SLE+ Connective Tissue 2.0 diagnostic has ... and that adoption continues to grow. The Avise ... Disease (CTD), including, but not limited to, Systemic ...
(Date:4/28/2015)... 28, 2015 Semler Scientific, Inc. (Nasdaq: ... develops, manufactures and markets patented products that assist healthcare ... announced that it has received an order from another ... country who offer Medicare Advantage programs. This brings the ... plans who are now customers of Semler. ...
(Date:4/28/2015)... 2015   HX360 today announced that ... inaugural HX360 Innovation Challenge competition, recognizing ... experience in hospital and health system settings.  The ... of eighty-three entries, with the four finalists presenting ... the HX360 Innovation Challenge program at HIMSS15 last ...
Breaking Medicine Technology:Exagen Sees Growing Adoption of Avise Diagnostic for Connective Tissue Disease with New Milestone 2Semler Adds Top Insurance Plan to Customer List 2Semler Adds Top Insurance Plan to Customer List 3Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3
...  BSI,s Healthcare Solutions Group is hosting a free webinar on ... is scheduled for January 26 and is intended to address ... how to be prepared. (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ... to help the audience understand the current status and upcoming ...
... (Nasdaq: CDXS ) today announced that the Company,s ... his decision to resign as Chief Financial Officer in order ... Board of Directors will conduct an immediate search for a ... contributions to Codexis," said Alan Shaw, Ph. D, President and ...
Cached Medicine Technology:FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 2015 As the Muscular Dystrophy ... services programs, the organization has hired Scientific Program ... MDA from Fidelity Biosciences Research Initiative where, as ... in neurodegenerative diseases such as Alzheimer’s Disease, and ... time at Fidelity, she was a junior faculty ...
(Date:4/28/2015)... 2015 Researchers from four US medical ... a steroid prior to pemetrexed (Alimta) chemotherapy may keep ... Click here to read the full story on ... Raabe College of Pharmacy in Ohio, Stanford Cancer Institute ... Healthcare in Kentucky gave a single dose of dexamethasone ...
(Date:4/28/2015)... 2015 SeniorCare.com has published the ... reality problem Americans have regarding aging and long-term care ... care services as they age, 63% of Americans do ... In the report, Carol Marak of SeniorCare.com interviewed 44 ... Health Care Association and The Scan Foundation. The experts ...
(Date:4/28/2015)... Enrollment in programs designed to coordinate ... in April, according to the editors of Atlantic ... Eligibles Database , an online subscription resource that ... community. This is a 14% increase since the ... January, but only covers about a quarter of ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2
... complicated. Thomas Jefferson University biochemistry researchers have shown ... insect molting hormone doesn,t activate and repress genes as once ... out-competed by a heme-binding receptor to repress the same genes ... For the last 20 years, the nuclear receptor known ...
... U.S. Food and Drug Administration and the National Institutes ... of tobacco users to monitor and assess the behavioral ... The initiative, called the Tobacco Control Act National Longitudinal ... collaboration on tobacco regulatory research since Congress granted FDA ...
... and diagnosis of open angle glaucoma important so that treatment ... developing to prevent or avoid further vision loss. Writing in ... Engineering and Informatics , researchers in the US have analyzed ... so that patients can be screened at an earlier stage ...
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Anemia ... have different types of surgery, not just heart operations, a ... anemia have worse outcomes after heart surgery, but anemia,s impact ... deficient in red blood cells. For the new ...
... had been given DES, the first synthetic form of estrogen, ... in the womb (in utero) is associated with many reproductive ... conditions. The results of this analysis, conducted by researchers at ... of Health, and collaborators across the country, were published Oct. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
Cached Medicine News:Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:FDA and NIH announce joint study on tobacco use and risk perceptions 2Health News:Detecting glaucoma before it blinds 2Health News:Anemia Could Add to Surgical Risks 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3
... Introducing the new large ... new handpieces function as both ... the ultimate in flexibility. Its ... always wanted with the security ...
... 7600 Oscillating Saw offers unparalleled ... thanks to its 14.4V NiMH ... head may be rotated into ... any plane and will accept ...
... Breakthrough in Battery Powered Orthopedic Systems., ... new addition to the Hall® Surgical line ... System is the first and only software ... market. It is a full-function orthopedic power ...
... Introducing the new large ... Our new handpieces function ... electric instruments, offering the ... the versatility the industry ...
Medicine Products: